Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00295503 · OUTCOME

Progression Free Survival Rate at 6 Months

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma · Source last updated 2020-10-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
patients progression free at 6 months

What was measured

This is the percentage of patients alive and progression-free at 6 months from initiation of treatment.

Groups in this outcome

Cisplatin, Pemetrexed, Bevacizumab

cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cisplatin, Pemetrexed, Bevacizumab52

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cisplatin, Pemetrexed, Bevacizumab56Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        56
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    units
    Participants
description
This is the percentage of patients alive and progression-free at 6 months from initiation of treatment.
groups
  1. description
    cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks
    id
    OG000
    title
    Cisplatin, Pemetrexed, Bevacizumab
param Type
NUMBER
reporting Status
POSTED
time Frame
patients progression free at 6 months
title
Progression Free Survival Rate at 6 Months
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice